Cristina Mussini discusses the current data on interleukin inhibitors for the treatment of COVID-19 and explores why tocilizumab has been associated with beneficial outcomes in some studies but not others.
Jinoos Yazdany discusses the rationale behind investigating these agents and explores the role of rheumatologists in ensuring they are studied as safely and efficiently as possible.
Views from professional organizations
Representatives from EULAR, the COVID-19 Global Rheumatology Alliance, and the Lupus Foundation of American identify the potential pitfalls to avoid when it comes to the repurposing of rheumatology drugs for COVID-19.
[Rheumatologists] can bring an extensive knowledge base to ensure that various immune modifiers that act across the range of immune effector function, can be trialled as safely and efficiently as possible.
Chair of the COVID–19 Global Rheumatology Alliance
While there is much suggestive observational data about a number of agents, definitive data can only come from randomized clinical trials so our efforts have to focus on them.
Vice President, Advocacy & Government Relations, Lupus Foundation of America
People with lupus rely greatly on hydroxychloroquine to treat the disease, including reducing disease activity and preventing flares and reducing organ damage.